Satellos Bioscience Inc. (MSCLF)
- Newsfile
Satellos Bioscience Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 ..
- Newsfile
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a
- Zacks Small Cap Research
MSCLF: Initiating Coverage of Satellos Biosciences; A Muscle Regeneration Company…
By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT We are initiating coverage of Satellos Biosciences Inc. (OTC:MSCLF) with a $0.70 valuation. Satellos is a biopharmaceutical company developing treatments for muscle diseases, including muscular dystrophies and muscle loss associated with chronic illness and aging. Satellos’ core technology is based on discoveries by its scientific
